4 results match your criteria: "University Hospital Centre Zagreb Department of Dermatology and Venereology[Affiliation]"
Acta Dermatovenerol Croat
August 2023
Daniela Ledic Drvar, MD, PhD, University Hospital Centre Zagreb Department of Dermatology and Venereology School of Medicine University of Zagreb, Zagreb, Croatia;
Dear Editor, Approximately 25-33% of cutaneous melanomas arise from nevi (1). Shitara et al. suggested that junctional and compound nevi are more likely give rise to melanoma than intradermal nevi, but this has not been definitively confirmed (2).
View Article and Find Full Text PDFActa Dermatovenerol Croat
November 2022
Anamaria Balić, MD, University Hospital Centre Zagreb Department of Dermatology and Venereology, Kišpatićeva 12, Zagreb, Croatia;
Acta Dermatovenerol Croat
August 2020
Daniela Ledić Drvar, MD, PhD, University Hospital Centre Zagreb Department of Dermatology and Venereology , School of Medicine University of Zagreb, 10000 Zagreb, Šalata 4, Croatia;
Multiple primary malignancies, including melanoma, usually present singly over time rather than simultaneously. Hovewer, approximatelly one third of the patients develop multiple primary melanomas. We present a case of a 57-year-old woman, with two grossly suspicious, unevenly pigmented lesions on her left lower leg measuring up to 8 and 11 mm.
View Article and Find Full Text PDFActa Dermatovenerol Croat
October 2018
Jaka Radoš, MD, University Hospital Centre Zagreb Department of Dermatology and Venereology School of Medicine University of Zagreb Šalata 4, 10000 Zagreb , Croatia;
Dear Editor,We present the case of a 40-year old male patient with lymphomatoid papulosis of a waxing and waning course on whom three biopsies were performed during a 14-year period with no change in histopathological or immunophenotypical characteristics. Lymphomatoid papulosis (LP) is a chronic, recurrent, self-healing papulonodular skin eruption with the histopathologic features of a cutaneous T-cell lymphoma but an often benign and indolent clinical course (1). It is designated as a primary, cutaneous, CD30+ lymphoproliferative disorder.
View Article and Find Full Text PDF